UK-based private equity company Pamplona Capital Management has agreed to acquire Parexel International Corporation by acquiring the entire outstanding shares of the company in an all-cash transaction.
The purchase consideration for the acquisition has been fixed at $88.1 per share, valuing the transaction at $5bn inclusive of net debt.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The target company is a biopharmaceutical firm based in the US and will become a privately held company following the acquisition, which is expected to be completed by this year's fourth quarter.
Spherix has reached an agreement to acquire a controlling stake in biopharmaceutical company, Hoth Therapeutics.
The acquirer company is a scientific research company also based in the US, and the acquisition is expected to increase Spherix’s shareholder value.
Quantum Hi-Tech China Biological has reached an agreement to acquire Shanghai ChemPartner, a contract research organisation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoth companies involved in the acquisition are based in China. The acquisition is expected to be completed by the end of the year.
